Transapical Beating-Heart Septal Myectomy for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Initial Clinical Experience

BACKGROUND: Nonobstructive hypertrophic cardiomyopathy (nHCM), defined as hypertrophic cardiomyopathy without left ventricular outflow tract obstruction, remains challenging to treat because of its heterogeneous pathophysiology. This study evaluated the safety and efficacy of transapical beating-heart septal myectomy in patients with symptomatic nHCM. METHODS: Patients with symptomatic, drug-refractory nHCM were prospectively enrolled to undergo transapical beating-heart septal myectomy through a left minithoracotomy. Under real-time transesophageal echocardiographic guidance, septal myectomy was tailored to relieve systolic cavity obliteration and mid-to-apical ventricular obstruction and to enlarge the left ventricular cavity. The primary end point was procedural success at 6 to 12 months postoperatively, defined as fulfillment of all prespecified criteria compared with baseline: ≥1-class improvement in New York Heart Association functional class, ≥10-point increase in Kansas City Cardiomyopathy Questionnaire score, ≥10-mL increase in stroke volume, and normal or grade I diastolic function. RESULTS: Between January 2023 and January 2025, 97 consecutive eligible patients with nHCM underwent transapical beating-heart septal myectomy at Tongji Hospital. At postoperative 6 to 12 months, procedural success was achieved in 87.6%. Specifically, New York Heart Association functional class I increased from 0% at baseline to 93.8% at follow-up, the median Kansas City Cardiomyopathy Questionnaire score improved from 64 (interquartile range, 56–69) to 87 (interquartile range, 82–92; P <0.001), the stroke volume increased from 53.5 mL (interquartile range, 41.0–66.6 mL) to 70.8 mL (interquartile range, 61.3–82.3 mL; P <0.001), and normal or grade I diastolic function increased from 65.6% to 97.9%. Among patients who underwent paired cardiopulmonary exercise testing (n=58), peak oxygen uptake increased by 1.1±2.9 mL/kg/min ( P =0.008). In an exploratory, hypothesis-generating analysis of 12 patients with paired 1 3 N-ammonia positron emission tomography, coronary flow reserve increased from 1.8±0.3 to 2.0±0.4 ( P =0.034). Adverse events included mitral valve injury (n=1) and ventricular septal perforation (n=1), the latter resulting in 1 postoperative death. CONCLUSIONS: Transapical beating-heart septal myectomy was associated with favorable left ventricular geometric remodeling and meaningful improvements in symptoms, health status, and functional capacity in selected patients with symptomatic nHCM. Being a potential therapeutic option for a previously difficult-to-treat population, it warrants further evaluation in controlled, multicenter studies. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05648825.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2026-11-16
DOI
https://doi.org/10.1161/circulationaha.126.082486
Primary Topic
Cardiomyopathy and Myosin Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Transapical Beating-Heart Septal Myectomy for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Initial Clinical Experience

Song Wan, Ying Yan Zhu, Yilei Ma, Xiang Wei et al.
4 links
Circulation
Cardiomyopathy and Myosin Studies
article

Transapical Beating-Heart Septal Myectomy for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Initial Clinical Experience

Song Wan, Ying Yan Zhu, Yilei Ma, Xiang Wei, Hartzell Vernon Schaff, Xiaohua Zhu, Chen Wang, Lin Cheng, Wei Zhou, Jing Fang, Yue Chen, Chaoyu Gong, Rui Li, Jitai Du, Taiqiang Chen, Qunhui Wang, Hui Wang, Jianyuan Zhou, Yani Liu
article en

Abstract

BACKGROUND: Nonobstructive hypertrophic cardiomyopathy (nHCM), defined as hypertrophic cardiomyopathy without left ventricular outflow tract obstruction, remains challenging to treat because of its heterogeneous pathophysiology. This study evaluated the safety and efficacy of transapical beating-heart septal myectomy in patients with symptomatic nHCM. METHODS: Patients with symptomatic, drug-refractory nHCM were prospectively enrolled to undergo transapical beating-heart septal myectomy through a left minithoracotomy. Under real-time transesophageal echocardiographic guidance, septal myectomy was tailored to relieve systolic cavity obliteration and mid-to-apical ventricular obstruction and to enlarge the left ventricular cavity. The primary end point was procedural success at 6 to 12 months postoperatively, defined as fulfillment of all prespecified criteria compared with baseline: ≥1-class improvement in New York Heart Association functional class, ≥10-point increase in Kansas City Cardiomyopathy Questionnaire score, ≥10-mL increase in stroke volume, and normal or grade I diastolic function. RESULTS: Between January 2023 and January 2025, 97 consecutive eligible patients with nHCM underwent transapical beating-heart septal myectomy at Tongji Hospital. At postoperative 6 to 12 months, procedural success was achieved in 87.6%. Specifically, New York Heart Association functional class I increased from 0% at baseline to 93.8% at follow-up, the median Kansas City Cardiomyopathy Questionnaire score improved from 64 (interquartile range, 56–69) to 87 (interquartile range, 82–92; P <0.001), the stroke volume increased from 53.5 mL (interquartile range, 41.0–66.6 mL) to 70.8 mL (interquartile range, 61.3–82.3 mL; P <0.001), and normal or grade I diastolic function increased from 65.6% to 97.9%. Among patients who underwent paired cardiopulmonary exercise testing (n=58), peak oxygen uptake increased by 1.1±2.9 mL/kg/min ( P =0.008). In an exploratory, hypothesis-generating analysis of 12 patients with paired 1 3 N-ammonia positron emission tomography, coronary flow reserve increased from 1.8±0.3 to 2.0±0.4 ( P =0.034). Adverse events included mitral valve injury (n=1) and ventricular septal perforation (n=1), the latter resulting in 1 postoperative death. CONCLUSIONS: Transapical beating-heart septal myectomy was associated with favorable left ventricular geometric remodeling and meaningful improvements in symptoms, health status, and functional capacity in selected patients with symptomatic nHCM. Being a potential therapeutic option for a previously difficult-to-treat population, it warrants further evaluation in controlled, multicenter studies. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05648825.

CirculationVol. 154(20)
Mayo Clinic (US), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Tongji Hospital (CN), Huazhong University of Science and Technology (CN)
Good health and well-being
Cardiomyopathy and Myosin Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon